BMS, Novartis Partner on Opdivo Combo

Source: Nasdaq

Jun 08, 2017

Novartis has entered into a clinical research collaboration with Bristol-Myers Squibb for a possible combo treatment for metastatic colorectal cancer.

According to the agreement, BMS will investigate the safety, tolerability, and efficacy of Novartis's Mekinist in combination with BMS’ own Opdivo and Opdivo plus Yervoy regimen.

Since its Opdivo and Yervoy combination regimen became the first immuno-oncology combination approved for the treatment of metastatic melanoma in 2015, BMS has continued to evaluate Opdivo alone or in combination therapies with Yervoy and other anti-cancer agents.

 Read the Nasdaq coverage


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments